ArticleVaccines2026
Measles and Rubella Immunity Profile of Healthcare Workers in Bulgaria: A Cross-Sectional Study.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Healthcare workers (HCWs) and medical providers are regularly exposed to a wide range of infectious diseases in the course of their duties. This occupational risk is significant in the context of highly contagious infections such as measles, which can spread rapidly in healthcare institutions. This study aimed to assess the seroprevalence of protective anti-measles and anti-rubella IgG antibodies and factors influencing immunity among HCWs across all 28 districts in Bulgaria.
methodsA total of 1854 individuals, including 540 (29%) doctors and 1314 (71%) medical specialists from all 28 districts in Bulgaria, were screened for protective immunity against measles and rubella. Serum samples were analyzed for the presence of protective IgG antibodies by ELISA (Enzyme-Linked Immunosorbent Assay) using commercial EUROIMMUN Anti-Measles/Anti-Rubella Virus IgG ELISA kits. According to the manufacturer's instructions, the results were interpreted semi-quantitatively as positive, negative, and equivocal.
resultsAnti-measles protective IgG antibodies were detected in 86.1% of participants for measles and in 95.2% for rubella. Our study found a statistically significant difference when analyzing demographic factors (age) for measles: the samples from older participants (over 50-year-old persons) were characterized by higher immunity levels; staff working in non-infectious-disease wards (
conclusionsHCWs are at a greater risk of contracting infections than the general public because they have contact with sick patients or infectious material. Their vaccination or IgG immunity status must be strictly monitored, especially to limit the spread of nosocomial infections in hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.